Immunological impact of autologous peripheral blood stem cell infusion on lung adenocarcinoma

doi:10.3969/j.issn.2095-4344.2017.09.017

Abstract

Abstract:

BACKGROUND: Although clinical methods for autologous peripheral blood stem cell separation and identification are relatively more, there is no unified standard. Moreover, little is reported on immune effects on lung adenocarcinoma during autologous peripheral blood stem cell transplantation.
OBJECTIVE: To study the effect of autologous peripheral blood stem cell transplantation on immunological function of lung adenocarcinoma rats by exploring the separation and identification methods of autologous peripheral blood stem cells.
METHODS: The mononuclear cells were isolated from the peripheral blood of Wistar rats by density gradient centrifugation method and then identified. Eighteen Wistar rats were randomly divided into routine treatment group and cell transplantation group, with nine rats in each group. Animal models of lung adenocarcinoma were established in the rats, and underwent no treatment in the routine treatment group but injection of autologous peripheral blood stem cell suspension (0.2 mL, 2.5×10⁶/L) via the tail vein in the cell transplantation group. Immune indicators were detected in two groups after treatment. Three rats from each group were anesthetized and scarified at 4, 10, 14 days after treatment, respectively. Afterwards, we detected the effects of autologous peripheral blood stem cell transplantation on immunological function of lung adenocarcinoma rats.
RESULTS AND CONCLUSION: Newly isolated mononuclear cells from rat peripheral blood showed a round or oval shape and were relatively small in size. After 5 days of culture, autologous peripheral blood stem cells grew rapidly, and the round cells began to spread to both ends and became spindle-shaped, thereby forming small colonies. Autologous peripheral blood stem cells induced in vitro experienced three stages successively: cell arrest, logarithmic and plateau phases. Flow cytometry showed that sorted cells were identified as autologous peripheral blood stem cells by expressing CD90, CD133 and Flk-1. After 4, 10 and 14 days culture, the expression of CD133 increased first and then descended, and Flk-1 showed an increasing trend. Compared with the routine treatment group, the expression of tumor necrosis factor-α induced protein 6 in the cell transplantation group was significantly higher (P < 0.05), while the expression of nuclear factor κB was significantly lower (P < 0.05). In conclusion, the isolation and identification methods of autologous peripheral blood stem cells are simple and can be used to secrete a large number of nutritional factors in the treatment of lung adenocarcinoma, which can enhance body immunity in the treatment.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

Key words: Peripheral Blood Stem Cell Transplantation, Lung Neoplasms, Adenocarcinoma, Cell Separation, Immunity, Tissue Engineering

CLC Number:

R394.2

Wang Mei-jiang, Qi Lin. Immunological impact of autologous peripheral blood stem cell infusion on lung adenocarcinoma[J]. Chinese Journal of Tissue Engineering Research, 2017, 21(9): 1402-1407.

Figures/Tables 4

References

[1] 朱雄增,张杰.肺腺癌IASLC/ATS/ERS国际多学科分类解读[J].临床与实验病理学杂志,2012,28(3):241-244.

[2] Warth A,Muley T,Meister M,et al.The novel histologic International Association for the Study of Lung Cancer / American Thoracic Society / European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.J Clin Oncol. 2012; 30(13): 1438-1446.

[3] 刘标,周晓军.非小细胞肺癌个体化治疗的靶向分子检测[J].临床与实验病理学杂志,2012,28(8):831-837.

[4] Russell P A,Wainer Z,Wright G M,et al. Does lung adenocarci noma subtype predict patient survival? A clinicopathologic study based on the new International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary lung adenocarcinoma classification.J Thoracic Oncol. 2011;6( 9) : 1496-1504.

[5] Warth A,Stenzinger A,von Brünneck A C,et al. Interobserver variability in the application of the novel IASLC/ATS/ERS classifi-cation for pulmonary adenocarcinomas. Eur Respir J. 2012;40(5):1221-1227.

[6] 章必成,杨波,刘健,等. 肺腺癌瘤周微淋巴管密度的检测及其预后意义[J].临床肿瘤学杂志,2010,15(11): 978-981.

[7] 张力. 脑转移瘤的诊断和治疗[C].中华医学会第五届全国胸部肿瘤及内窥镜学术会议论文汇编,2011.

[8] Motoi N,Szoke J,Riely GJ,et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes,EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008;32(6): 810-827.

[9] 刘丽,姜建威.肺腺癌新增分类及研究新进展[J]. 中华临床医师杂志:电子版,2014,8(6):1128-1133.

[10] Mc Carroll JA,Gan PP,Liu M,et al. β-Ⅲ-tubulin is a multi functional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. Cancer Res. 2010;70(12): 4995-5003.

[11] 石祥宇,庞青松,赵纲,等. 伴微乳头结构肺腺癌的研究进展[J]. 中国肺癌杂志,2015,18(11):701-705.

[12] Hung JJ,Yeh YC,Jeng WJ,et al. Predictive value of the international association for the study of lung cancer/American Thoracic Society/ European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival. J Clin Oncol. 2014;32(22): 2357-2364.

[13] 刘雨桃,石远凯,胡兴胜,等.吉非替尼治疗EGFR基因突变状态不明的青年晚期肺腺癌疗效分析[J].中国肺癌杂志,2014,17(5): 401-405.

[14] 丁粉干,刘标,张新华,等.不同肺腺癌分级评分系统在I期肺腺癌预后评估中的意义[J].中华病理学杂志,2012,41(3):145-150.

[15] Shi Y,Au JS,Thongprasert S,et al. A prospective,molecular epide miologystudy of EGFR mutations in Asian patients with advanced non -small - celllung cancer of adenocarcinoma histology(PIONEER). J Thorac Oncol. 2014;9(2):154 -162.

[16] 冯瑞娥.最新国际肺腺癌多学科分类中的病理分类及其临床意义[J].中华结核和呼吸杂志,2012,35(2):95-96.

[17] 金鑫,赵绍宏,高洁,等.纯磨玻璃密度肺腺癌病理分类及影像表现特点分析[J].中华放射学杂志,2014,48(4):283-287.

[18] Backos DS,Franklin CC,Reigan P. The role of glutathione in brain tumor drug resistance. Bio Chem Pharmacol. 2012; 83(8): 1005-1012.

[19] 周晓军,刘摇标.解读2011年IASLC/ATS/ERS肺腺癌国际多学科分类[J].临床与实验病理学杂志,2011,27(8):801-805.

[20] 刘颖汇,朱彦君,郭延林,等.肺腺癌中C/EBPα、MVD表达的临床意义及相关性分析[J].临床肺科杂志,2013,18(11):2057-2059.

[21] Fujikawa Y,Urano Y,Komatsu T,et al. Design and synthesis of highly sensitive fluorogenic substrates for glutathione S-transferase and application for activity imaging in living cells. Am Chem Soc. 2008;130(44): 14533-14543.

[22] 王凯,李晓军,陈芳芳,等. ID3 蛋白在肺腺癌中的表达及临床病理学意义[J].临床检验杂志,2011,29(2): 118-120.

[23] Citti A,Boldrini R,lnserra A,et al. Expression of multidrug resistance-associated proteins in paediatric soft tissue sarcomas before and after chemotherapy.Oncol. 2012;41(1): 117-124.

[24] Cao Y,Zhang L,Kamimura Y,et al. B7-H1 over-expression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin. Cancer Res.2011;71(4): 1235-1243.

[25] 史妍婷,井欢,王莹,等.补中益气汤含药血清逆转A549/DDP的顺铂耐药及对mTOR表达的影响[J].中国实验方剂学杂志,2013, 19(9):215-219.

[26] 季旭明,欧阳兵,吴智春,等.温下方含药血清诱导A549/DDP细胞凋亡及对Bcl-2,Bax,p53蛋白表达的影响[J].中国实验方剂学杂志,2011,17(12):123-126.

[27] Ye MX,Zhao YL, Li Y, et al. Curcumin reverses cis-platin resistance and promotes human lung adenocarcinoma A549 / DDP cell apoptosis through HIF-1α and caspase-3 mechanisms. Phytomedicine. 2012;19( /9): 779-787.

[28] 张莹,贾英杰,李小江,等.消岩汤对耐顺铂人肺腺癌A549/DDP细胞多药耐药基因调控作用的研究[J].药物评价研究,2014,37(6): 507-510.

[29] 张继新,崔力方,周全,等.肺腺癌转移至胸膜孤立性纤维性肿瘤临床病理观察[J].诊断病理学杂志,2014,21(3):145-148.

[30] 马云帆,范梦颖,陈克能.肺鳞癌与肺腺癌的免疫组化指标的诊断及预后意义[J].中国肺癌杂志,2014,17(6):506-510.

[31] 俎云芬,王熙才,刘馨,等.甲状腺转录因子在宣威肺腺癌中的表达及临床意义[J].中国肺癌杂志,2013,16(3):131-137.

[32] 王艳芬,刘标,徐艳,等.窖蛋白-1表达与肺腺癌临床病理特征和预后的关系[J].中华病理学杂志,2014,43(4):251-255.

[33] 张莹,贾英杰,李小江,等.注射用黄芪多糖对耐顺铂人肺腺癌细胞A549/DDP耐药逆转作用研究[J].药物评价研究,2012,35(6): 417-419.

[34] Kim TJ,Goo JM,Lee KW,et al. Clinical,pathological and thin-section CT features of persistent multiple ground glass opacity nodules: comparison with solitary ground-glass opacity nodule. Lung Cancer. 2009;64(2):171-178.

[35] Eisenberg RL,Bankier AA,Boiselle PM. Compliance with Fleischner Society guidelines for management of small lung nodules: a survey of 834 radiologists. Radiology. 2010;255(1): 218-224.

[36] Yoshizawa A,Motoi N,Riely GJ,et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24 (5):653-664.

[37] Sawada E,Nambu A,Motosugi U,et al. Localized mucinous bronchioloalveolar carcinoma of the lung: thin-section computed tomography and fluorodeoxyglucose positron emission tomography findings. Jpn J Radiol. 2010;28(4): 251-258.

[38] 唐晓勇,唐迎雪.浙贝母碱对肺癌A549/DDP细胞多药耐药的逆转作用观察及机制探讨[J].山东医药,2012,52(18):4-6.

[39] 李泽慧,安超,胡凯文,等.浙贝母总生物碱对人肺腺癌A549/顺铂细胞耐药性的逆转作用[J].中国药理学与毒理学杂志,2013, 27(3):315-320.

[40] Kim TJ,Park CM,Goo JM,et al. Is there a role for FDG PET in the management of lung cancer manifesting predominantly as ground-glass opacity? AJR Am J Roentgenol.2012;198(1): 83-88.

[41] Selle F, Gligorov J, Soares DG, et al. [High-dose chemotherapy as a strategy to overcome drug resistance in solid tumors].Bull Cancer. 2016;103(10):861-868.

[42] Buryk MA, Picarsic JL, Creary SE, et al. Identification of Unique, Heterozygous Germline Mutation, STK11 (p.F354L), in a Child with an Encapsulated Follicular Variant of Papillary Thyroid Carcinoma within Six Months of Completing Treatment for Neuroblastoma. Pediatr Dev Pathol. 2015;18(4): 318-323.

[43] Terunuma H. Autologous Immune Enhancement Therapy for Cancer - Our experience since 2004. J Stem Cells Regen Med. 2012;8(3):205-206.

[44] Taniguchi A, Takigawa N, Hotta K, et al. [A relapse of small-cell lung cancer ten years after concomitant chemoradiotherapy followed by high-dose chemotherapy with autologous peripheral blood stem cell transfusion]. Nihon Kokyuki Gakkai Zasshi. 2011;49(9):697-701.

[45] Terashita S, Hirano K, Hirai T, et al.[Successful treatment of small cell lung cancer with secondary immune thrombocytopenic purpura]. Nihon Kokyuki Gakkai Zasshi. 2009;47(11):1036-1040.

[46] Hah JO. Intensive chemotherapy with autologous PBSCT for advanced adrenocortical carcinoma in a child. J Pediatr Hematol Oncol. 2008;30(4):332-334.

[47] Stemmer SM, Hardan I, Brenner HJ, et al. High-dose chemotherapy and autologous stem cell transplant in women with de novo chemosensitive metastatic breast cancer. Am J Clin Oncol. 2004;27(3):250-255.

[48] Hotta K, Ueoka H, Kiura K, et al. Successful treatment of limited disease-small cell lung cancer with multimodality treatment consisting of concurrent chemoradiotherapy, high-dose chemotherapy with autologous peripheral blood stem cell transplantation and surgical resection. Intern Med. 2003;42(12):1223-1227.

[49] Ziske C, Gorschlüter M, Mey U, et al. Sequential high-dose chemotherapy with autologous stem cell support in patients with limited-stage small cell lung cancer. Anticancer Res. 2002;22(6B):3723-3726.